» Articles » PMID: 35153531

Black Fungus Outbreak in India - A Direct Consequence of COVID-19 Surge: A Myth or Reality

Overview
Journal Gondwana Res
Date 2022 Feb 14
PMID 35153531
Authors
Affiliations
Soon will be listed here.
Abstract

The deadly second wave of COVID-19 has seen an unprecedented surge in mucormycosis associated mortality in India, overwhelming the heath authorities with challenges beyond measure. Also known as black fungus, this life-threatening fungal infection usually manifests in the nose, spreads to the eyes, and in some cases also to the brain. Immune suppression, pre-existing conditions, prolonged and indiscriminate use of steroids, and unhygienic environments are some of the widely recognized risk factors for contracting black fungus in individuals recovered from COVID-19. However, diagnosis of the infection remains insufficient due to the lack a holistic understanding of the possible risks, symptoms, and exposure pathways and therefore no definite protocol exists for managing this fatal infection. Here, we synthesize the current state of knowledge on black fungus outbreak in India and identify key gaps in its understanding with respect to potential risk factors leading to the widespread infection. We looked at 3354 black fungus cases in India, enlisting ailment history (particularly diabetes) and steroid usage in COVID-19 patients as the key factors responsible for exacerbating risks associated with the disease. However, we also press on the possibilities that other less studied non-traditional risk factors may also have a role in causing the infection. Black fungus is therefore a reality of COVID-19, with or without diabetes or steroid use needs to be investigated. We believe such a review is imperative for making informed decisions specially around timely diagnosis and channelizing efforts in controlling the spread of COVID-19 associated mucormycosis.

Citing Articles

Air pollution in five Indian megacities during the Christmas and New Year celebration amidst COVID-19 pandemic.

Kumar R, Samuel C, Raju S, Gautam S Stoch Environ Res Risk Assess. 2022; 36(11):3653-3683.

PMID: 35401048 PMC: 8976463. DOI: 10.1007/s00477-022-02214-1.

References
1.
Garg D, Muthu V, Sehgal I, Ramachandran R, Kaur H, Bhalla A . Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia. 2021; 186(2):289-298. PMC: 7862973. DOI: 10.1007/s11046-021-00528-2. View

2.
Duffy J, Harris J, Gade L, Sehulster L, Newhouse E, OConnell H . Mucormycosis outbreak associated with hospital linens. Pediatr Infect Dis J. 2014; 33(5):472-6. DOI: 10.1097/INF.0000000000000261. View

3.
Krishnappa D, Naganur S, Palanisamy D, Kasinadhuni G . Cardiac mucormycosis: a case report. Eur Heart J Case Rep. 2019; 3(3). PMC: 6764552. DOI: 10.1093/ehjcr/ytz130. View

4.
Banerjee M, Pal R, Bhadada S . Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India. Postgrad Med J. 2023; 98(e2):e108-e109. DOI: 10.1136/postgradmedj-2021-140537. View

5.
Gautam S, Hens L . SARS-CoV-2 pandemic in India: what might we expect?. Environ Dev Sustain. 2020; 22(5):3867-3869. PMC: 7166000. DOI: 10.1007/s10668-020-00739-5. View